FDA Clears Two Exalenz Bio H. pylori Systems

Mar 13, 2018

|

NEW YORK (GenomeWeb) – The US Food and Drug Administration has cleared a point-of-care and a lab system from Exalenz Bioscience for detecting Helicobacter pylori bacteria in children between the ages of three and 17.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

FDA Clears Two Exalenz Bio H. pylori Systems

To read the full story....

Breaking News

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

German Stores to Begin Selling COVID-19 Rapid Antigen Tests for Home Use

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

DermTech Q4 Revenues Up 31 Percent

In Brief This Week: Abbott Laboratories, LexaGene, Caris Life Sciences, SQI Diagnostics, and More

Featured White Papers

What's Popular?

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

Dx Developers Hedge on SARS-Cov-2 Rapid Antigen Tests, Citing Conflicting FDA Messages

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

Abbott SARS-CoV-2 IgG Antibody Test Receives Emergency Use Authorization from FDA

FDA Expands Approval of Pfizer's Lorbrena to First-Line ALK-Positive NSCLC; Approves Roche CDx

Sponsorships